论文部分内容阅读
目的观察单独应用鬼臼乙叉甙(VP16)静脉给药5d治疗老年人小细胞肺癌的临床效果及其毒性反应。方法30例老年人小细胞肺癌患者,采用VP16单药静脉化疗。结果完全缓解9例(30.0%)、部分缓解15例(50.0%)、微效4例(13.3%)、稳定1例(3.3%)、进展1例(3.3%),有效率80.0%。全组中位生存期15个月,其中有效者中位生存时间20.5个月,无效者中位生存时间8个月,两者比较有显著性差异(P=0.013)。1、2、3年生存率分别为66.7%、40.0%、20.0%。毒性反应较轻,患者均能耐受,以轻度骨髓抑制和肝功能受损为主,恶心、呕吐少见。结论静脉5d单独用VP16治疗老年人小细胞肺癌的疗效可靠、使用方便、毒副反应轻。
Objective To observe the clinical effects and toxicity of intravenous administration of etoposide (VP16) for 5 days in elderly patients with small cell lung cancer. Methods Thirty elderly patients with small cell lung cancer were treated with VP16 single drug intravenous chemotherapy. Results The complete remission was achieved in 9 cases (30.0%), partial remission in 15 cases (50.0%), slight effect in 4 cases (13.3%), stabilization in 1 case (3.3%) and progression in 1 case (3.3%). The median survival time of the whole group was 15 months, of which the effective median survival time was 20.5 months and the median effective life span was 8 months. There was a significant difference between the two groups (P = 0.013). The 1, 2, 3 year survival rates were 66.7%, 40.0% and 20.0% respectively. Toxic reactions are mild, patients can tolerate, with mild myelosuppression and impaired liver function, nausea, vomiting rare. Conclusions Vein 5d alone VP16 for the treatment of elderly patients with small cell lung cancer reliable, easy to use, toxic side effects.